Glyoxalase 1 Polymorphisms in Schizophrenia Patients and Healthy Controls

This study recruited 1214 patients (801 males and 406 females) with schizophrenia from the Department of Psychiatry at the Affiliated Hospital of Guangdong Medical University from October 2012 and February 2023. All patients were diagnosed independently by two experienced senior psychiatrists according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) or Fifth Edition (DSM-5). The excluded criteria included any physical disease, psychosis due to general medical conditions, other mental illnesses (e.g., major depression, bipolar disorder, manic episode, anxiety disorder). The Positive and Negative Syndrome Scale (PANSS) was used to evaluate psychotic symptoms. The 1138 healthy controls (734 males and 404 females), who without the histories of major psychiatric disorders, serious physical disease or substance abuse were recruited from the same geographical area. The study protocol was reviewed and approved by the ethics committee of Guangdong Medical University (IRB number, PJ2017058). All subjects or their relatives provided informed consent to participate in the study.

本研究于2012年10月至2023年2月期间，从广东医科大学附属医院精神科招募了1214名精神分裂症患者（其中男性801例，女性406例）。所有患者均由2名经验丰富的资深精神科医师依据《精神障碍诊断与统计手册》第四版（Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, DSM-IV）或第五版（Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, DSM-5）的诊断标准独立完成诊断。本研究的排除标准包括合并任何躯体疾病、躯体疾病所致精神障碍，以及其他精神疾病（如重度抑郁症、双相障碍、躁狂发作、焦虑障碍）。本研究采用阳性与阴性症状量表（Positive and Negative Syndrome Scale, PANSS）评估受试者的精神病性症状。同期从同一地理区域招募了1138名健康对照者（其中男性734例，女性404例），所有对照者均无重性精神疾病、严重躯体疾病或物质滥用史。本研究方案经广东医科大学伦理委员会审查批准（伦理审查编号：PJ2017058），所有受试者或其家属均已签署知情同意书，同意参与本研究。